The Brain NGF Metabolic Pathway in Health and in Alzheimer’s Pathology
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Emerging research has re-emphasized the role of the cortical cholinergic system in the symptomology and progression of Alzheimer’s disease (AD). Basal forebrain (BF) cholinergic nuclei depend on target-derived NGF for survival during development and for the maintenance of a classical cholinergic phenotype during adulthood. In AD, BF cholinergic neurons lose their cholinergic phenotype and function, suggesting an impairment in NGF-mediated trophic support. We propose that alterations to the enzymatic pathway that controls the maturation of proNGF to mature NGF and the latter’s ulterior degradation underlie this pathological process. Indeed, the NGF metabolic pathway has been demonstrated to be impaired in AD and other amyloid pathologies, and pharmacological manipulation of NGF metabolism has consequences in vivo for both levels of proNGF/NGF and the phenotype of BF cholinergic neurons. The NGF pathway may also have potential as a biomarker of cognitive decline in AD, as its changes can predict future cognitive decline in patients with Down syndrome as they develop preclinical Alzheimer’s pathology. New evidence suggests that the cholinergic system, and by extension NGF, may have a greater role in the progression of AD than previously realized, as changes to the BF precede and predict changes to the entorhinal cortex, as anticholinergic drugs increase odds of developing AD, and as the use of donepezil can reduce rates of hippocampal and cortical thinning. These findings suggest that new, more sophisticated cholinergic therapies should be capable of preserving the basal forebrain thus having profound positive effects as treatments for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050
Nerve Growth Factor Treatment After Brain Injury Prevents Neuronal Death
Kromer, L. F. (1987) · Science · doi:10.1126/science.3798108 · Cited by 932 · cited 4×
“A number of thorough experimental studies confirmed the ability of exogenous NGF (both recombinant and isolated from the maxillary gland) to support NGF–dependent cholinergic nuclei of the BF (nucleus basalis and medial septum) following their disconnection from the sites of NGF production (Sofroniew et al., 1983; Sof…”
BackgroundInfluentialRisacher, S. L., McDonald, B. C., Tallman, E. F., West, J. D., Farlow, M. R., Unverzagt, F. W., Gao, S., Boustani, M., Crane, P. K., Petersen, R. C., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0580 · Cited by 350
Hartikka, J., & Hefti, F. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-08-02967.1988 · Cited by 317
Anticholinergic drug use and risk for dementia: target for dementia prevention
Jessen, F., Kaduszkiewicz, H., Daerr, M., Bickel, H., Pentzek, M., Riedel-Heller, S., Wagner, M., Weyerer, S., Wiese, B., van den Bussche, H., et al. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-010-0156-4 · Cited by 119 · cited 1×
“Conversely, recent studies provide evidence of brain atrophy and increased risk of dementia and AD in non-demented individuals receiving long term (over 3 years) medications with drugs possessing primary or secondary anti-cholinergic properties (Jessen et al., 2010; Gray and Hanlon, 2016; Risacher et al., 2016; Chuang…”
BackgroundIulita, M. F., Ower, A., Barone, C., Pentz, R., Gubert, P., Romano, C., Cantarella, R. A., Elia, F., Buono, S., Recupero, M., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.05.001 · Cited by 99
Self-citation
Cited by
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360
“NGF is a neurotrophic factor essential for the survival and homeostasis of basal forebrain cholinergic neurons whose selective degeneration critically contributes to cognitive decline in AD patients (132, 133).”
BackgroundSelf-citationReimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies
Xhima, K., Markham-Coultes, K., Hahn Kofoed, R., Saragovi, H. U., Hynynen, K., & Aubert, I. (2022) · Brain · doi:10.1093/brain/awab460 · Cited by 43
Pentz, R., Iulita, M. F., Mikutra-Cencora, M., Ducatenzeiler, A., Bennett, D. A., & Cuello, A. C. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105150 · Cited by 31
Self-citationBaldassarro, V. A., Cescatti, M., Rocco, M. L., Aloe, L., Lorenzini, L., Giardino, L., & Calzà, L. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1111170 · Cited by 26
Metadata
- Authors
- Cuello, A. C., Pentz, R., & Hall, H.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2019-02-12
- Volume
- 13
- Pages
- 62-62
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2912352250
- Cited by
- 108
- References
- 12
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Brain NGF Metabolic Pathway in Health and in Alzheimer’s Pathology. https://app.cochat.ai/papers/10.3389/fnins.2019.00062
- The paper
- Cuello, A. C., Pentz, R., & Hall, H. (2019). The Brain NGF Metabolic Pathway in Health and in Alzheimer’s Pathology. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2019.00062
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.